← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Other protein kinase inhibitors
pexidartinib
L01EX15
Adult Dosing
- 125 mg orally twice daily on an empty stomach (1 hour before or 2 hours after a meal)
- Continue treatment until disease progression or unacceptable toxicity
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery
Mechanism of Action
- Small-molecule tyrosine kinase inhibitor targeting CSF1R (colony stimulating factor 1 receptor), KIT, and FLT3
- Inhibition of CSF1R decreases the proliferation of macrophages and tumor cells expressing CSF1 in tenosynovial giant cell tumors
Contraindications
- Severe hepatic impairment
- Concomitant use with strong CYP3A inducers
- Pregnancy and lactation
Adverse Reactions
- Hepatotoxicity (including mixed or hepatocellular liver injury with jaundice and fatal outcomes)
- Increased lactate dehydrogenase (LDH)
- Increased AST and ALT
- Hair color changes
- Fatigue
- Edema
- Rash
- Dysgeusia
- Vomiting
Drug Interactions
- Strong CYP3A inducers significantly decrease pexidartinib exposure; concomitant use is contraindicated
- Strong CYP3A inhibitors may increase pexidartinib exposure; monitor for toxicity
- Hepatotoxic drugs may increase the risk of severe liver injury; avoid concomitant use
Curated Content: Needs Vetting Before Put to Clinical Use